# US 2021/0171978 A1 · Gene-modified nonhuman animal model

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171978 A1
- Document ID: US20210171978A1
- Status: Published application
- Kind: A1
- Application number: 16/771,541
- Filed: 2018-12-06
- Published: 2021-06-10
- Earliest claimed: 2017-12-13
- Assignees: Hamamatsu Photonics K.K.
- Applicants: Hamamatsu Photonics K.K.
- Inventors: Iori OHMORI; Mamoru OUCHIDA; Tomoji MASHIMO
- Web page: https://patentgrep.com/patent/US20210171978A1

## CPC

- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- C12N 9/0036: {acting on NADH or NADPH (1.6)}
- A01K 2217/03: Animals modified by random mutagenesis, e.g. using ENU, chemicals
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2227/105: Murine
- A01K 2267/035: Animal model for multifactorial diseases
- C12N 2015/8527: {for producing animal models, e.g. for tests or diseases}
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided is a nonhuman animal model that is obtained by modifying a gene encoding thioredoxin and useful as a disease model of aging, kidney diseases, cardiovascular diseases, hypertension, aortic dissection, chronic obstructive lung disease, age-dependent epilepsy, abnormality of lipid metabolism, anemia, osteoporosis, abnormal immunity, etc. These variety of phenotypes are caused by the fact that a modification of a gene encoding thioredoxin induces hypofunction of thioredoxin expressed in multiple organs throughout the body. The gene encoding thioredoxin is a gene selected from among TXN, TRX, TRX1, RRDX, Txn1, Txn, Trx1 and ADF.

## Claims

### Claim 1

A non-human model animal in which a gene encoding thioredoxin is modified.

### Claim 2 (depends on 1)

The non-human model animal according to claim 1, wherein the modified gene encoding thioredoxin decrease an amount of NADPH (nicotinamide adenine dinucleotide phosphate) consumed per unit time to reduce a disulfide bond of a substrate protein and a decrease rate thereof is in a range of 10% to 90%.

### Claim 3 (depends on 1)

The non-human model animal according to claim 1, wherein the animal is adapted as a disease model selected from the group consisting of aging, kidney disease, cardiovascular disease, hypertension, aortic dissection, chronic obstructive pulmonary disease, age-dependent epilepsy, dyslipidemia, anemia, osteoporosis and immune disorder.

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The non-human model animal according to claim 2, wherein the animal is adapted as a disease model selected from the group consisting of aging, kidney disease, cardiovascular disease, hypertension, aortic dissection, chronic obstructive pulmonary disease, age-dependent epilepsy, dyslipidemia, anemia, osteoporosis and immune disorder.

### Claim 6 (depends on 1)

A method for screening a drug, wherein the method uses the non-human model animal according to claim 1.

### Claim 7 (depends on 2)

A method for screening a drug, wherein the method uses the non-human model animal according to claim 2.

### Claim 8 (depends on 3)

A method for screening a drug, wherein the method uses the non-human model animal according to claim 3.

### Claim 9 (depends on 5)

A method for screening a drug, wherein the method uses the non-human model animal according to claim 5.
